BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10939600)

  • 1. A phase II study of paclitaxel/cisplatin combination in patients with metastatic breast cancer refractory to anthracycline-based chemotherapy.
    Rosati G; Riccardi F; Tucci A; De Rosa P; Pacilio G
    Tumori; 2000; 86(3):207-10. PubMed ID: 10939600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
    Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP
    Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
    Frasci G; Comella P; D'Aiuto G; Budillon A; Barbarulo D; Thomas R; Capasso I; Casaretti R; Daponte A; Caponigro F; Gravina A; Maiorino L; Caratení G; Gentile A; Comella G
    Breast Cancer Res Treat; 1998 May; 49(1):13-26. PubMed ID: 9694607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.
    Gianni L; Munzone E; Capri G; Villani F; Spreafico C; Tarenzi E; Fulfaro F; Caraceni A; Martini C; Laffranchi A
    J Natl Cancer Inst; 1995 Aug; 87(15):1169-75. PubMed ID: 7674322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines.
    Vassilomanolakis M; Koumakis G; Barbounis V; Demiri M; Pateras H; Efremidis AP
    Ann Oncol; 2000 Sep; 11(9):1155-60. PubMed ID: 11061611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure.
    Martín M; Lluch A; Casado A; Garciía Carbonero I; de Paz L; Esteban C; Insa A; Alfonso R; García-Conde J; Diaz-Rubio E
    Ann Oncol; 2000 Jan; 11(1):85-9. PubMed ID: 10690393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
    Murad AM
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.
    Wasserheit C; Frazein A; Oratz R; Sorich J; Downey A; Hochster H; Chachoua A; Wernz J; Zeleniuch-Jacquotte A; Blum R; Speyer J
    J Clin Oncol; 1996 Jul; 14(7):1993-9. PubMed ID: 8683229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage treatment with epirubicin and/or paclitaxel in metastatic breast cancer patients relapsed after high-dose chemotherapy with peripheral blood progenitor cells.
    Tartarone A; Sirotovà Z; Aieta M; Lelli G
    Tumori; 2001; 87(3):134-7. PubMed ID: 11504366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.
    Gelmon KA; O'Reilly SE; Tolcher AW; Campbell C; Bryce C; Ragaz J; Coppin C; Plenderleith IH; Ayers D; McDermott B; Nakashima L; Healey D; Onetto N
    J Clin Oncol; 1996 Apr; 14(4):1185-91. PubMed ID: 8648373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant advanced breast cancer: a phase II study.
    Polyzos A; Tsavaris N; Kosmas C; Gogas H; Toufexi H; Kosmidis C; Markopoulos C; Giannopoulos A; Papadopoulos O; Stamatiadis D; Kouraklis G
    J Chemother; 2003 Dec; 15(6):607-12. PubMed ID: 14998089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.
    Nicholson BP; Paul DM; Hande KR; Shyr Y; Meshad M; Cohen A; Johnson DH
    Clin Breast Cancer; 2000 Jul; 1(2):136-43; discussion 144. PubMed ID: 11899652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer.
    Kourousis C; Kakolyris S; Androulakis N; Heras P; Vlachonicolis J; Vamvakas L; Vlata M; Hatzidaki D; Samonis G; Georgoulias V
    Am J Clin Oncol; 1998 Jun; 21(3):226-32. PubMed ID: 9626786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
    Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial.
    Donadio M; Manzin E; Berruti A; Bottini A; Gorzegno G; Danese S; DeFabiani E; Sarobba MG; Lorusso V; Castiglione F; Moro G; Bertetto O; Bumma C; Dogliotti L
    Cancer Chemother Pharmacol; 2001 May; 47(5):391-6. PubMed ID: 11391853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial.
    Xu B; Jiang Z; Kim SB; Yu S; Feng J; Malzyner A; Del Giglio A; Chung HC; Shen LJ; Pen DL
    Breast Cancer; 2011 Jul; 18(3):203-12. PubMed ID: 21465229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.